Grant of Share Options to Chief Executive Officer
Shield Therapeutics PLC announced on October 13, 2025, the grant of share options to its Group CEO, Anders Lundstrom, under the company's Retention and Performance Share Plan (RPSP) as part of his 2025 annual equity grant. Lundstrom, a person discharging managerial responsibility, received options over 1,547,262 ordinary shares. These options vest in three equal tranches over three years from the grant date, contingent on his continued employment. The option awards represent approximately 0.1% of the total number of AIM securities currently in issue. The exercise price for these options is 1.5 pence per share. Lundstrom currently holds 585,000 ordinary shares in the company.
Select text to share a quote on X · sign in to keep highlights & notes in your STX notes
London, UK, 14 October 2025: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that on 13 October 2025 it granted share awards in the form of options over ordinary shares in the capital of the Company ("Ordinary Shares") under Shield Therapeutics' Retention and Performance Share Plan ("RPSP") to the Group CEO as part of his 2025 annual equity grant.
In accordance with the requirements of the EU Market Abuse Regulations the following options have been granted to Anders Lundstrom, Chief Executive Officer, who is deemed a PDMR:
| Name | Option Plan | Number of Ordinary Shares under Option | Vesting Date |
|---|---|---|---|
| Anders Lundstrom | RPSP | 1,547,262 | Three equal traches over three years from the date of grant, subject to Mr Lundstrom remaining in office as at the date of vesting. |
The proportion of total option awards to Anders Lundstrom is approximately 0.1% of the total number of AIM securities in issue at this time.
Anders Lundstrom currently holds 585,000 ordinary shares in the Company.
| a) | Name | Anders Lundstrom |
| 2. | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/ amendment | Initial Notification |
| 3. | Details of the Issuer | |
| a) | Name | Shield Therapeutics plc |
| b) | LEI code | 213800G74QWY15FC3W71 |
| a) | Description of the financial instrument Identification code | Options over new Ordinary Shares ISIN: GB00BYV81293 |
| b) | Nature of the transaction | Grant of awards over new Ordinary Shares under the Company's Retention and Performance Share Plan. |
| c) | Price(s) and volumes(s) | 2025 RPSP Award Price (£) Volume 0.015 1,547,262 |
| d) | Aggregated information - Aggregate volume - Price | Awards granted over 1,547,262 shares in total 1.5p exercise price |
| e) | Date of the transaction | 13 October 2025 |
| f) | Place of the transaction | Outside of trading venue |
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.